Methyl-CpG Binding Protein 2 in Alzheimer Dementia

키워드

참고문헌 (83)

1. Alzheimer’s Association, "2019 Alzheimer’s disease facts and figures", Alzheimers Dement, 15, pp.321~387 (2019)
2. Selkoe DJ, "The amyloid hypothesis of Alzheimer’s disease at 25 years", EMBO Mol Med, 8, pp.595~608 (2016)
3. Karch CM, "Alzheimer’s disease risk genes and mechanisms of disease pathogenesis", Biol Psychiatry, 77, pp.43~51 (2015)
4. Makin S, "The amyloid hypothesis on trial", Nature, 559, pp.S4~7 (2018)
5. Mullard A, "Anti-amyloid failures stack up as Alzheimer antibody flops", Nat Rev Drug Discov (2019)[DOI]
6. Lambert JC, "Meta-analysis of 74, 046 individuals identifies 11new susceptibility loci for Alzheimer’s disease", Nat Genet, 45, pp.1452~1458 (2013)
7. Kunkle BW, "Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Abeta, tau, immunity and lipid processing", Nat Genet, 51, pp.414~430 (2019)
8. Congdon EE, "Tau-targeting therapies for Alzheimer disease", Nat Rev Neurol, 14, pp.399~415 (2018)
9. Villemagne VL, "Imaging tau and amyloid-beta proteinopathies in Alzheimer disease and other conditions", Nat Rev Neurol, 14, pp.225~236 (2018)
10. Heneka MT, "Neuroinflammation in Alzheimer’s disease", Lancet Neurol, 14, pp.388~405 (2015)
11. Heneka MT, "Innate immunity in Alzheimer’s disease", Nat Immunol, 16, pp.229~236 (2015)
12. Ransohoff RM, "How neuroinflammation contributes to neurodegeneration", Science, 353, pp.777~783 (2016)
13. Chinta SJ, "Cellular senescence and the aging brain", Exp Gerontol, 68, pp.3~7 (2015)
14. Coppe JP, "Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor", PLoS Biol, 6, pp.2853~2868 (2008)
15. Bussian TJ, "Clearance of senescent glial cells prevents tau-dependent pathology and cognitive decline", Nature, 562, pp.578~582 (2018)
16. Zhang P, "Senolytic therapy alleviates Abeta-associated oligodendrocyte progenitor cell senescence and cognitive deficits in an Alzheimer’s disease model", Nat Neurosci, 22, pp.719~728 (2019)
17. Jones PL, "Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription", Nat Genet, 19, pp.187~191 (1998)
18. Nan X, "Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex", Nature, 393, pp.386~389 (1998)
19. Fuks F, "The methyl-CpG-binding protein MeCP2 links DNA methylation to histone methylation", J Biol Chem, 278, pp.4035~4040 (2003)
20. Chahrour M, "MeCP2, a key contributor to neurological disease, activates and represses transcription", Science, 320, pp.1224~1229 (2008)
21. Chen WG, "Derepression of BDNF transcription involves calcium-dependent phosphorylation of MeCP2", Science, 302, pp.885~889 (2003)
22. Zhou Z, "Brain-specific phosphorylation of MeCP2 regulates activity-dependent Bdnf transcription, dendritic growth, and spine maturation", Neuron, 52, pp.255~269 (2006)
23. Chao HT, "MeCP2 controls excitatory synaptic strength by regulating glutamatergic synapse number", Neuron, 56, pp.58~65 (2007)
24. Nelson ED, "MeCP2-dependent transcriptional repression regulates excitatory neurotransmission", Curr Biol, 16, pp.710~716 (2006)
25. Patrizi A, "Accelerated hyper-maturation of parvalbumin circuits in the absence of MeCP2", Cereb Cortex, pp.bhz085~ (2019)[DOI]
26. Shahbazian MD, "Insight into Rett syndrome : MeCP2 levels display tissue-and cell-specific differences and correlate with neuronal maturation", Human Molecular Genetics, 11, pp.115~124 (2002)
27. Smrt RD, "Mecp2 deficiency leads to delayed maturation and altered gene expression in hippocampal neurons", Neurobiol Dis, 27, pp.77~89 (2007)
28. Amir RE, "Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2", Nature Genetics, 23, pp.185~188 (1999)
29. Wan M, "Rett syndrome and beyond : recurrent spontaneous and familial MECP2 mutations at CpG hotspots", Am J Hum Genet, 65, pp.1520~1529 (1999)
30. Arulmani Manavalan, "Brain site-specific proteome changes in aging-related dementia", Experimental and Molecular Medicine, 45(9), pp.1~17 (2013), 생화학분자생물학회
31. Choi J, "Hyperoxygenation revitalizes Alzheimer’s disease pathology through the upregulation of neurotrophic factors", Aging Cell, 18, pp.e12888~ (2019)
32. Lin Q, "Control of mouse cardiac morphogenesis and myogenesis by transcription factor MEF2C", Science, 276, pp.1404~1407 (1997)
33. Lin Q, "Requirement of the MADS-box transcription factor MEF2C for vascular development", Development, 125, pp.4565~4574 (1998)
34. Li H, "Transcription factor MEF2C influences neural stem", progenitor cell differentiation and maturation in vivo, 2008, pp.105, 9397~9402
35. Mao Z, "Neuronal activity-dependent cell survival mediated by transcription factor MEF2", Science, 286, pp.785~790 (1999)
36. Cole CJ, "MEF2 negatively regulates learning-induced structural plasticity and memory formation", Nat Neurosci, 15, pp.1255~1264 (2012)
37. Le Meur N, "MEF2C haploinsufficiency caused by either microdeletion of the 5q14.3 region or mutation is responsible for severe mental retardation with stereotypic movements, epilepsy and", or cerebral malformations, 2010, pp.47, 22~29
38. Han K, "Human-specific regulation of MeCP2 levels in fetal brains by microRNA miR-483-5p", Genes Dev, 27, pp.485~490 (2013)
39. Kuhn PH, "ADAM10 is the physiologically relevant, constitutive alphasecretase of the amyloid precursor protein in primary neurons", EMBO J, 29, pp.3020~3032 (2010)
40. Kim M, "Potential late-onset Alzheimer’s disease-associated mutations in the ADAM10 gene attenuate {alpha}-secretase activity", Hum Mol Genet, 18, pp.3987~3996 (2009)
41. Suh J, "ADAM10 missense mutations potentiate beta-amyloid accumulation by impairing prodomain chaperone function", Neuron, 80, pp.385~401 (2013)
42. De Strooper B, "The secretases : enzymes with therapeutic potential in Alzheimer disease", Nat Rev Neurol, 6, pp.99~107 (2010)
43. Wang YM, "MicroRNA-197 controls ADAM10 expression to mediate MeCP2’s role in the differentiation of neuronal progenitors", Cell Death Differ, 26, pp.1863~1879 (2019)
44. Long JZ, "The secreted enzyme PM20D1 regulates lipidated amino acid uncouplers of mitochondria", Cell, 166, pp.424~435 (2016)
45. Sanchez-Mut JV, "PM20D1 is a quantitative trait locus associated with Alzheimer’s disease", Nat Med, 24, pp.598~603 (2018)
46. Kumar A, "Epigenetic regulation of presenilin 1 and 2in the cerebral cortex of mice during development", Dev Neurobiol, 75, pp.1165~1173 (2015)
47. Wang C, "The effect of Mecp2 on heart failure", Cell Physiol Biochem, 47, pp.2380~2387 (2018)
48. Sierant M, "Evaluation of BACE1 silencing in cellular models", Int J Alzheimers Dis, 2009, pp.257403~ (2009)[DOI]
49. Bie B, "Epigenetic suppression of neuroligin 1 underlies amyloid-induced memory deficiency", Nat Neurosci, 17, pp.223~231 (2014)
50. Roux JC, "Modification of Mecp2 dosage alters axonal transport through the Huntingtin", Hap1 pathway, 2012, pp.45, 786~795
51. Maphis NM, "Whole genome expression analysis in a mouse model of tauopathy identifies MECP2 as a possible regulator of tau pathology", Front Mol Neurosci, 10, pp.69~ (2017)[DOI]
52. Montgomery KR, "Elevated MeCP2 in mice causes neurodegeneration involving tau dysregulation and excitotoxicity : implications for the understanding and treatment of MeCP2 triplication syndrome", Mol Neurobiol, 55, pp.9057~9074 (2018)
53. Hynd MR, "Glutamate-mediated excitotoxicity and neurodegeneration in Alzheimer’s disease", Neurochem Int, 45, pp.583~595 (2004)
54. LeBlanc AC, "The role of apoptotic pathways in Alzheimer’s disease neurodegeneration and cell death", Curr Alzheimer Res, 2, pp.389~402 (2005)
55. Bracaglia G, "Methyl-CpG-binding protein 2 is phosphorylated by homeodomain-interacting protein kinase 2 and contributes to apoptosis", EMBO Rep, 10, pp.1327~1333 (2009)
56. Petazzi P, "An increase in MECP2 dosage impairs neural tube formation", Neurobiol Dis, 67, pp.49~56 (2014)
57. Tsujimura K, "Neuronal differentiation of neural precursor cells is promoted by the methyl-CpG-binding protein MeCP2", Exp Neurol, 219, pp.104~111 (2009)
58. Dastidar SG, "Isoform-specific toxicity of Mecp2 in postmitotic neurons : suppression of neurotoxicity by FoxG1", J Neurosci, 32, pp.2846~2855 (2012)
59. Williams AA, "Apoptotic activity of MeCP2 is enhanced by C-terminal truncating mutations", PLoS One, 11, pp.e0159632~ (2016)
60. Russell JC, "Enhanced cell death in MeCP2 null cerebellar granule neurons exposed to excitotoxicity and hypoxia", Neuroscience, 150, pp.563~574 (2007)
61. Jin LW, "Dysregulation of glutamine transporter SNAT1 in Rett syndrome microglia : a mechanism for mitochondrial dysfunction and neurotoxicity", J Neurosci, 35, pp.2516~2529 (2015)
62. Ballas N, "Non-cell autonomous influence of MeCP2-deficient glia on neuronal dendritic morphology", Nat Neurosci, 12, pp.311~317 (2009)
63. Roux JC, "Treatment with desipramine improves breathing and survival in a mouse model for Rett syndrome", Eur J Neurosci, 25, pp.1915~1922 (2007)
64. Roux JC, "Progressive noradrenergic deficits in the locus coeruleus of Mecp2 deficient mice", J Neurosci Res, 88, pp.1500~1509 (2010)
65. Panayotis N, "Morphological and functional alterations in the substantia nigra pars compacta of the Mecp2-null mouse", Neurobiol Dis, 41, pp.385~397 (2011)
66. Palmer A, "MeCP2 mutation causes distinguishable phases of acute and chronic defects in synaptogenesis and maintenance, respectively", Mol Cell Neurosci, 37, pp.794~807 (2008)
67. Brichta L, "Identification of neurodegenerative factors using translatome-regulatory network analysis", Nat Neurosci, 18, pp.1325~1333 (2015)
68. Gil J, "Cellular senescence causes ageing", Nat Rev Mol Cell Biol, 20, pp.388~ (2019)
69. Baker DJ, "Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders", Nature, 479, pp.232~236 (2011)
70. Baar MP, "Targeted apoptosis of senescent cells restores tissue homeostasis in response to chemotoxicity and aging", Cell, 169, pp.132~147 (2017)
71. Zhang W, "Comparison of global DNA methylation profiles in replicative versus premature senescence", Life Sci, 83, pp.475~480 (2008)
72. Sanders YY, "Epigenetic mechanisms regulate NADPH oxidase-4 expression in cellular senescence", Free Radic Biol Med, 79, pp.197~205 (2015)
73. Wang C, "MeCP2-mediated epigenetic regulation in senescent endothelial progenitor cells", Stem Cell Res Ther, 9, pp.87~ (2018)
74. Ohashi M, "Loss of MECP2 Leads to Activation of P53 and Neuronal Senescence", Stem Cell Reports, 10, pp.1453~1463 (2018)
75. Squillaro T, "A case report : bone marrow mesenchymal stem cells from a Rett syndrome patient are prone to senescence and show a lower degree of apoptosis", J Cell Biochem, 103, pp.1877~1885 (2008)
76. Squillaro T, "Reduced expression of MECP2 affects cell commitment and maintenance in neurons by triggering senescence : new perspective for Rett syndrome", Mol Biol Cell, 23, pp.1435~1445 (2012)
77. Squillaro T, "Senescence phenomena and metabolic alteration in mesenchymal stromal cells from a mouse model of Rett syndrome", Int J Mol Sci, 20(10), pp.E2508~ (2019)[DOI]
78. Squillaro T, "Partial silencing of methyl cytosine protein binding 2(MECP2)in mesenchymal stem cells induces senescence with an increase in damaged DNA", FASEB J, 24, pp.1593~1603 (2010)
79. Van Esch H, "MECP2 duplication syndrome", Mol Syndromol, 2, pp.128~136 (2012)
80. Zeev BB, "Rett syndrome : clinical manifestations in males with MECP2 mutations", J Child Neurol, 17, pp.20~24 (2002)
81. Ward CS, "Loss of MeCP2 causes urological dysfunction and contributes to death by kidney failure in mouse models of Rett syndrome", PLoS One, 11, pp.e0165550~ (2016)
82. Sadegh MK, "Detrusor induction of miR-132", 212 following bladder outlet obstruction : association with MeCP2 repression and cell viability, 2015, pp.10, e0116784~
83. Kashyap M, "Bladder overactivity involves overexpression of MicroRNA 132 and nerve growth factor", Life Sci, 167, pp.98~104 (2016)

관련 논문AI추천